ARS Pharmaceuticals 3Q 2026: Revenue $37.71M, EPS ($0.36) — 10-Q Summary

ARS Pharmaceuticals’ revenue increased from the prior-year quarter, primarily on higher global neffy unit sales. Net loss narrowed as operating expenses fell, mainly due to lower marketing-related expenses, partly offset by increased R&D costs that included a technology in-license.Financial Highlig…